F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

Tang discusses the limitations in available data, but nonetheless high potential, of SBRT in kidney cancer. As Tang noted in his ASTRO 2024 presentation topic, SBRT has been linked to significantly ...

ART post-RC in MIBC patients shows no significant increase in acute or late toxicity, with mild bowel toxicity being more frequent. Historical concerns about bowel exposure have limited ART use, but ...

Aquablation offers a versatile treatment for BPH, accommodating various prostate sizes and shapes, with a relatively flat learning curve for urologists. Proper patient selection is crucial for ...

The study evaluates Focal One robotic HIFU for BPH, focusing on safety and efficacy in a phase 1/2 trial. Phase 1 determines optimal treatment parameters, while phase 2 expands enrollment to assess ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

Combining AR and neuroendocrine marker expressions helps identify metastatic castration-sensitive prostate cancer (mCSPC) patient subgroups with different prognoses. Baseline AR and neuroendocrine ...

Zaorsky discusses the patient safety misconceptions around radiotherapy for RCC, and considering patient-reported outcomes in future randomized controlled trials. New data presented at the American ...

Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction. Patients with specific genetic mutations may benefit more from targeted therapies than ...

Androgen deprivation therapy significantly increases depression risk in prostate cancer patients, with a 60% higher incidence rate. White patients on androgen deprivation therapy are more likely to be ...